Share on StockTwits

Theravance (NASDAQ:THRX) SVP Bradford J. Shafer unloaded 28,156 shares of Theravance stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $22.13, for a total value of $623,092.28. Following the completion of the transaction, the senior vice president now directly owns 446,274 shares in the company, valued at approximately $9,876,044. The sale was disclosed in a legal filing with the SEC, which is available at this link.

A number of analysts have recently weighed in on THRX shares. Analysts at Zacks reiterated a “neutral” rating on shares of Theravance in a research note on Friday, August 8th. They now have a $23.00 price target on the stock. Separately, analysts at Morgan Stanley downgraded shares of Theravance from a “buy” rating to a “neutral” rating in a research note on Thursday, July 24th. They now have a $31.00 price target on the stock, down previously from $34.00. Finally, analysts at Bank of America downgraded shares of Theravance from a “buy” rating to a “neutral” rating in a research note on Thursday, July 24th. They now have a $31.00 price target on the stock, down previously from $34.00. One analyst has rated the stock with a sell rating and six have given a hold rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $22.60.

Shares of Theravance (NASDAQ:THRX) traded up 1.03% on Wednesday, hitting $22.63. 431,977 shares of the company’s stock traded hands. Theravance has a 52-week low of $20.2337 and a 52-week high of $34.5286. The stock’s 50-day moving average is $26.23 and its 200-day moving average is $25.94. The company’s market cap is $2.603 billion. Theravance also saw a large drop in short interest during the month of July. As of July 31st, there was short interest totalling 21,928,363 shares, a drop of 7.1% from the July 15th total of 23,592,563 shares. Approximately 28.1% of the shares of the company are short sold. Based on an average trading volume of 1,256,758 shares, the days-to-cover ratio is currently 17.4 days.

Theravance (NASDAQ:THRX) last released its earnings data on Wednesday, August 6th. The company reported ($0.57) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.44) by $0.13. The company had revenue of $0.93 million for the quarter, compared to the consensus estimate of $4.39 million. During the same quarter last year, the company posted ($0.37) earnings per share. Theravance’s revenue was down 29.3% compared to the same quarter last year. On average, analysts predict that Theravance will post $-1.15 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which is scheduled for Thursday, September 18th. Shareholders of record on Thursday, August 28th will be given a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a yield of 4.46%. The ex-dividend date is Tuesday, August 26th.

Theravance, Inc (NASDAQ:THRX) is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.